Sign in
← Compounds

Tesofensine

peptide · headlineResearch use only

Serotonin reuptake inhibition

Summary

Tesofensine is a triple monoamine reuptake inhibitor (SNDRI) studied for appetite suppression and weight loss. Originally developed for neurodegenerative diseases, it showed significant weight reduction in clinical trials for obesity.

How it works

  • Serotonin reuptake inhibition
  • Noradrenaline reuptake inhibition
  • Dopamine reuptake inhibition

Dosing

  • unit: mg
    low dose: 0.25
    frequency: once daily
    high dose: 1
    standard dose: 0.5
    administration route: Oral

Cycling

  • Recommended frequency: 1x daily, preferably in the morning to avoid potential insomnia. Continuous use, with regular monitoring of weight, metabolic parameters, and potential side effects.

Side effects

common: ["Dry mouth","Constipation","Insomnia"]
warnings: ["Potential for increased blood pressure","Not recommended for patients with cardiovascular disease"]
long term: ["Effects on long-term safety and mortality not fully established"]

Chemistry & PK

half life: 20-22 hours
degradation: Primarily hepatic metabolism
molecular weight: 328.28
molecular formula: C17H23Cl2NO
tissue specificity: Affects central nervous system receptors

Verified citations

2 · PubMed-checked
  • Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: RCT.clinicalPMID 18950853 ↗
  • Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.clinicalPMID 18356831 ↗

Used for

Legal / compounding

Research use only

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.